AU621819B2 - Procaine acid complexes - Google Patents

Description

BRgis/ Registerec. PatentAttorney To: The Commissioner of Patents 'COMMONWEALTH OF AUSTRALIA w :j i

II;:

L

COMMONWEALTH OF AUSTRALIA Patent Act 1952 COMPLETE SPECIFICATION

(ORIGINAL)

Class 1 8t. Class Class Int. Class Application Number Lodged Complete Specification Lodged Accepted Published ioaA l a u0II 0 I 0 CO 0 C C SC7 o 00 005 0) 01,1 0001i Priority Related Art Name of Applicant Address of Applicant ROBERT KOCH 9401 South 1300 West, South Jordan, Utah 84065 United States of America ROBERT KOCH F.B. RICE CO., Patent Attorneys, 28A Montague Street, BALMAIN 2041.

Actual Inventor/-- Address for Service Complete Specification for the invention entitled: PROCAINE ACID COMPLEXES The following statement is a full description of this invention including the best method of performing it known to Ws/me:-

I_

2 PROCAINE DOUBLE SALT COMPLEXES This invention relates to double salt complexes between procaine salts and various biologically active organic acids. More particularly, this invention relates to double salt complexes between a procaine salt and one or more biologically active acids which exhibit vitamin or other useful biological activity.

Procaine is a widely known local anesthetic and is the 2-diethylaminoethyl ester of p-aminobenzoic acid. In its hydrochloride salt form, it is soluble in water and commonly used under its tradename Novocaine. Other salts are also known such as the nitrate, butyrate, borate and hydrobromide salts. Procaine hydrochloride is the most commonly used salt and was discovered in about 1905 as a replacement for the highly addictive local anesthetic, cocaine. By 1960 its use in the United States alone had oreached about 377,000 pounds.

SOnce absorbed, the procaine hydrochloride salt is rapidly hydrolyzed by plasma cholinesterase into p-amino benzoic acid (PABA) and diethylaminoethanol (DEAE).

PABA is a well known vitamin which is often considered necessary for growth of poultry, for the growth of healthy intestinal flora, and for the maintenance of a normal fur coat in fur producing animals. It has also been suggested as a vitamin which functions in the processes dealing with skin and hair pigmentation. Also, PABA is an intermediate in the preparation of other vitamins such as folic acid, biotin, niac.n and B 12 DEAE is also biologically active. It is closely 30 related to its adjacent homolog dimethylaminoethanol 0 4 O (DMAE) which is precursor of the vitamin choline. DEAE also participates in the synthesis of choline and acetylcholine. DEAE has also been reported to produce mental stimulation, mild euphoria and, unlike other mental stimulants such as amphetamines, has no adverse side r o 3 effects such as depression.

For many years, procaine, and procaine compositions used alone or stabilized by benzoic acid have been studied for their use in the treatment of depression and/or use in gerontology. There have been numerous studies and reports published on the advantages of procaine therapy. Procaine formulations known as or marketed under tradenames GH3 or Gerovital H3 as well as other procaine formulations are widely marketed outside the United States without prescription. Detailed information on various clinical studies of procaine formulations in the treatment of aging and depression are contained in a book by Herbert Bailey, "GH3-Will It Keep You Young Longer?", 1977, Bantham Books, Inc., New York, New York.

4 15 Studies have shown that both procaine and PABA act at the level of cell membrane metabolism. However, one of the disadvantages of administering procaine, either orally o or by injection, is that it is hydrolyzed so rapidly by a 4 the cholinesterase enzyme that it does not penetrate or cross the cell membrane as effectively as is desired. The half life of procaine in human serum at 370 C. is stated to be only about 0.52 to .30 of a minute. It has been shown that PABA and DEAE administered as a mixture do not Cf. possess the same biological activity as does procaine.

It would therefore be desirable to have a formulation that would protect the procaine molecule from hydrolysis by the colinesterase enzyme while not interfering with the ability of procaine to penetrate the cell membrane wall.

Solutions containing 1.3-6.5 moles of caffeine per mole of procaine have been shown to inhibit procaine hydrolysis in aqueous solutions. Also, aqueous solutions of about 0.1 mole benzoic acid per mole or procaine have been suggested as inhibiting hydrolysis. However, there appears to be no definitive studies showing that either caffeine or benzoic acid in serum solutions will inhibit the cholinesterase 4 enzyme from rapidly hydrolyzing the procaine molecule.

Moreover, caffeine is a CNS stimulant and its coadministration with procaine may be contraindicated.

Also, benzoic acid, although of relatively low toxicity, is a bacterioside and not readily metabolized. It combines with glycine as a conjugate forming hippuric acid which is removed through the urine. Because of its properties, benzoic acid has not been reacted with procaine in stoichiometric amounts. Thus, even if it were to protect procaine from rapid hydrolysis, it would only protect a minor amount.

German Offenlegungsschrift 26 22 622, published December 9, 1976, teaches simple salts formed by reacting procaine base with nicotinic acid. This nicotinate salt 0o 15 is said to have the capacity to permeate, cell membranes, o o particularly nerve cells, and become involved in cell 0 regeneration metabolism. As such, the salt is said to be 0 0 0 So the active ingredient in treatment of the aged, o o particularly in improving learning potential and memory 20 capacity. However, the product prepared from the 0 0 combination of procaine base and nicotinic acid is a single salt having a different structure from the double salts claimed herein. When procaine base is reacted with O" an acid such as nicotinic acid, the acid assoc'ates on the 0o 25 diethylamino nitrogen as shown by Formula I: 00 0.

o 0 C 2

H

5 0 II /N SC O-CH 2

CH

2 N H O0 0 0 C, 00 0

NH

2 1 The nicotinate salt of Formula I is a vitreous amorphous compound having no defined melting point. If one then attempts to form a hydrochloride salt of the compound of Formula I the HC1 associates with the pyridinyl nitrogen of the nicotinic acid forming the compound of Formula II: 0 C 2

H

5 0 +H Cl"

/N

1 C 0-CH 2

CH

2 -N H+ "O-C/

C

2

H

NH2 0 The compound of Formula II is a white crystalline 0o' o compound with a melting point of between about 218-2230 o o"o C. with some decomposition.

0 oo 0 o00 It is an object of the present invention to provide a double salt complex formed by the combination of a procaine salt and a beneficial biologically active organic acid which protects the procaine from rapid hydrolysis by od0 cholinesterase.

oltn It is also an object of the present invention to 0 a 25 provide double salt complexes of procaine salts with bioactive organic acids which readily cross the cell membrane barrier and assist in cellular repair.

Another object of this invention is to provide double o salt complexes of a procaine salt and vitamin or other o 4 ,o 30 biologically useful acids wherein the double salt complex serves as a carrier means for assisting the transfer of the acid across the cell membrane.

These and other objects may be accomplished by complexing procaine hydrochloride, with at least a stoichiometric amount of one or more bioactive acids.

SThese acids are selected from the group consisting of v:~Mn I i I i- -4 6 vitamin acids, essential unsaturated fatty acids, C 4 to

C

6 hydroxy carboxylic acids, and alpha amino acids.

Preferably, these acids will be selected from the group consisting of nicotinic acid, folic acid, biotin, citric acid and ascorbic acid. Other bioactive acids which can also be used include pantothenic acid, orotic acid, aspartic acid, succinic acid, fumaric acid, gluconic acid, methionine, tryptophane, tyrosine, glycine, dimethylglycine, glutamic acid, gamma linolenic acid and linoleic acid.

These acids form stable double salt complexes which are thought to remain primarily intact when being orally ingested and pass through the digestive tract, are oo transported through mucosal membranes and into the blood oo .oo 15 where they are transported to the cell site where the 0000 0 complexes are separated into their individual components 0 00 o 0.0 and utilized in the manner taught in the prior art or for o 00 cellular repair.

000 0 .oooo Complexes between a procaine salt and the bioactive 0 0 0 acids can be made by combining, in stoichiometric ratios, the complexing acid with the procaine salt in suitable solvents such as water, water-alcohol mixtures, acetone or acetone-alcohol mixtures and heat or vacuum concentrating 00ooo00 oO 'a depending on stability.

When a jalt is formed from procaine base and an acid, such as hydrochloric acid, the acid associates with the a C diethylamino nitrogen to form the acid addition salt shown in Formula III: o, 30 0 C O-CH2CH 2 -N H Cl"

C

2

H

NH

2 7 By combining the hydrochloride salt of Formula III with stoichiometric amounts of a vitamin acid, such as nicotinic acid, the double salt procaine hydrochloride nicotinate is formed as shown in Formula IV: 0 C 2

H

C O-CH 2

CH

2 -N H+ Cl-

C

2

H

0 15 NH 3 0o0 This is a totally different compound from the "0 0" procaine nicotinate illustrated in German 0 a 0 o co Offenlegungsschrift 26 22 622 referred to above. The 0"0. 20 double salt of Formula IV has the HC1 bonded to the diethylamino nitrogen with the nicotinic acid associating on the p-amino nitrogen of the p-amino benzoic acid portion of the molecule. This compound is a well defined 0000 0oooo white crystalline salt having a mole weight of 395.38 and 00"' 25 a melting point of between 195 and 200 0 C. Because of its distribution of electrical charges, the compound of 0 Formula IV tends to cause the complex to double back upon itself causing a tighter structure which, in turn, increases the protection of the ester linkage between the S 30 p-amino benzoic acid and diethylaminoethanol portions of w the procaine molecule. This in turn provides greater protection against enzymatic cleavage of the procaine molecule. The double salt of Formula IV has a greater positive ion effect because of double ionization. This increases cell membrane polarization and effective net membrane charge. This increases the transfer rate of the 0 i 8 complex across the membrane into the cell either through receptor cite mediated transport or through endocytosic transfer.

The other complexes of procaine HC1 with the organic acids mentioned, because of the organic acids linking to the p-amino nitrogen, produces the same type of increased protection of the ester linkage as just described. These double salts of procaine HC1, with the various organic acids and/or other possible biologically active compounds that shown an affinity to complex with the procaine HC1 molecule, provides an abundance of non-toxic'cellular nutrients that can provide either general"or specific oo nutrition to damaged, diseased cells that can be tailored to address specific or general problems.

"oo 15 Whatever double salt complex is formed using a 0 00 .o procaine salt and an organic acid, it will fall within the S00 oa scope of the following Formula V: o0000o 0 0 0 0000 ooo C O-CH 2

CH

2 -N H Cl-

C

2

H

NH

3

A-

i- 30 wherein A is the anion of biologically beneficial organic acids selected from the group consisting of vitamin acids, essential unsaturated fatty acids, C 4 to

C

6 hydroxycarboxylic acids, and alpha amino acids.

L LIYI- ii I i~

JP

9 Within that group the preferred anion combination for A is made up of anions from acids selected from the group consisting of nicotinic acid, folic acid, biotin, citric acid, ascorbic acid, pantothenic acid, succinic acid, fumaric acid, gluconic acid, linolenic acid, linoleic acid, methionine, tryptophane, tyrosine, glycine, dimethylglycine and glutamic acid. Most particularly preferred within the A anion grouping are anions from acids selected from the gr'oup consisting of nicotinic acid, folic acid, biotin, ascorbic acid and citric acid, Illustrative complexes of vitamin acids or citric acid within the above groupings are contained in Table I as follows: 00 2 0 0 Go 00 aa 0 0 000 0 0 0 0 00 0 0 0 0000 0 0 0000 0000 00 1 O a 00 61 I 1 0. 0 1 I V w TABLE I STRUCTUREHOEEIT FORMULA HOLE WEIGHT 0

C

2 H 11 C -O-CH 2

CH

2 N flt i c 2

H

I II '0CCl-C1T ti Cl- 713.68 14H C NHCH 2 N J Procaine Folic Acid Double Salt Complex 0 C O-CB 2

CHN

C 2 115 El clvii

C

2 11 0

NH

3 -0 C -CH 2

CII

2

CH

2

CH

2

/C\

IIN Nfl HC CII CI Ci 516.59 Procaine Biotine Double Salt Complex o C Cc, C COO TABLE I STRUCTURE FORMULA

NO.

MOLEWEIGHT

VIII

0 .HCHN C 2 215

NH

3 -O-C CHI CH -CH 2

OH

c- C HO 0 Procaine Ascorbic Acid Double Salt Complex 488.41

IX

0 C 2

H

C -U-C 2

C[

2 N H /11OOC

C

2

H

C H 2

NH

3 -0-C C-OH C1- 464.41 C 11 2 Procaine Citric Acid Double Salt Complex C, 00 C 0 o o0 (7 0 0 0 00 0 0

I

C

12 I o Ii 1; V I Similar complexes may be formed using the other acids such as orotic acid, aspartic acid, succinic acid, fumaric acid, gluconic acid, pantothenic acid, linolenic acid, linoleic acid and various alpha amino acids such as tyrosine, tryptophane, methionine, glycine, dimethylglycine and glutamic acid.

The double salt complex is formed beginning with procaine hydrochloride, i.e. the hydrochloride bonded to the diethylamino nitrogen. The pH for forming the double salt will depend upon the particular organic acid being but will generally be in the acid range of about 2.5 to 6.8.

The most preferable complexes are those formed from complexing a mixture of various vitamin acids with procaine hydrochloride to form an intricate composition consisting cf procaine hydrochloride complexed with various acids and also, wherein the various complexed double salt molecules are crosslinked with each other.

For example, when using a complexing acid mixture 20 containing an excess of citric and/or folic acids, these acids most probably cause additional crosslinking between the various complexes due to the trihydric nature of the citric acid and the dihydric nature of the folic acid.

Thus, while the exact structural formula of the complexes formed from a mixture of organic acids is subject to variation, it is known that there is a chemical interaction between the various procaine double salt complexes. This is also manifest in the demonstrated biological activity. Mixtures of a single procaine salt, such a procaine hydrochloride, and the various acids do not provide the same result as does administration of the double salt complexes formed from the same acids. Taking the reaction a step further, crosslinked complexes formed by the interaction between various double salt complexes, in many cases, have enhanced biological activity over an isolated double salt complex made of only a single -i -13 biologically active organic acid.

When selecting the vitamin acid or mixture of vitamin acids to utilize in forming a procaine double salt complex, it is often advantageous to keep in mind the recommended amount of vitamin acid to be consumed on a daily basis, the U.S. Recommended Daily Allowance RDA) as well as the dosage of procaine desired.

The Lollowing examples illustrate the methods of preparing procaine salt-vitamin acid complexes.

EXAMPLE I Into a heated round bottom flask was placed 360 mls of distilled water which was heated to 90-950 C. To the heated water was added 1.02 grams (0.0023 moles) of USP folic acid and stirred until dissolved. There was then added 272.27 grams (1 mole) of procaine hydrochloride which was dissolved. The heat was then turned off and there was added in succession, with each ingredient being oo dissolved into the mixture before adding the next, 42.6 grams (0.346 moles) of USP nicotinic acid, 1.05 (0.0043 moles) grams of d-biotin USP, 68.86 grams (0.391 moles) of ascorbic acid USP, 68.78 grams (0.358 moles) of USP citric acid, 64.00 grams USP potassium chloride and 75.45 grams of USP magnesium o sulfate (MgSO 4 7H20).

To this hot mixture was added a proper amount of microcrystalline cellulose mixed with 16 gm USP magnesium oxide as a carrier and the mixture was dried at 55 0

C.

for 24 hours. A granular mixture was obtained to which was added stearic acid as a lubricant. This mixture was S. 30 formed into tablets weighing between 500 to 510 milligrams, each tablet containing 100 mg. of procaine hydrochloride complexed with 16 mg. nicotinic acid, 0.4 mg. folic acid, 0.3 mg. biotin, 25 mg. ascorbic acid, 25 mg. citric acid, 11 mg. pocassium and 4 mg. magnesium.

The ratios of ingredients making up the procaine -14 hydrochloride complexes were determined by the current U.S. RDP's for the vitamin ingredients.

Preparation of Individual Procaine-Vitamin Acid Complexes In forming the following complexes, the solvents utilized were determined by the solubility of the reactive ingredients used. When using procaine HC1, these complexes are best formed using water, water-ethanol or water-acetone combinations.

When tablets are to be formed, it may be more efficient not to isolate the complex from the solvent, although that can be done if desired. However, it may be preferable to add the excipients to the complex in the solvent with mixing to form a granulated mixture directly Sfrom the solvent.

EXAMPLE II 1:1 Complex of Procaine HC1 and Nicotinic Acid- (Procaine HC1 Nicotinate) To 50 mls. of boiling water was added 27.2 grams (0.1 mole) of procaine HC1 with stirring until completely dissolved. With stirring was added 12.3 grams (0.1 mole) of nicotinic acid. This mixture was heated at the boiling point until clear. The solution was allowed to cool and a i white crystalline precipitate formed which was separated in a Buchner funnel and washed twice with 5.0 aliquots of cold distilled water. The product was dried to fine white crystals which were moderately soluble in water and ethanol. The crystals had a melting point between 195-200 0 C. In contrast, a 1:1 molar mixture of procaine HC1 and nicotinic acid melts at 145-150 0

C.

EXAMPLE III 1:1 Complex of Procaine HC1 and Folic Acid (Procaine HC1 Folate) Into a 105 mls of boiling water was dissolved 13.6 grams (0.05 mole) of procaine HC1,. To this solution was slowly added in 2 to 4 gram increments 22 grams (0.05 mole) of .s '51

:U

I

folic acid. Each folic acid increment added was dissolved before the next increment was added. The solution was cooled and the precipitate formed was filtered and dried.

A reddish/orange crystalline product was obtained which had no melting point. The crystals darken and char above 220 0

C.

EXAMPLE IV 1:1 Complex of Procaine HCl and Biotin (Procaine HCl Biotinate) Into a hot solution of 50 mls of ethanol and 30 mis of water was dissolved 2.72 grams (0.01 mole) of procaine HC1. To this was added 2.44 grams (0.01 mole) of biotin and heat was maintained until the ingredients reacted and c the solution cleared. On cooling, crystallization took place easily. White crystalline platelets were filtered, washed and dried. These crystals were partly soluble in o o swater and ethanol and had a melting point of about o 212-2150C.

o The procaine double salt complexes formed function by taking advantage of the ability of the procaine double salt to pass through the cell membrane, particularly through damaged or diseased cell membranes. The I complexing acids added to the p-amino group initially act '00 to sterically protect the procaine molecule from being attacked by the cholinesterase enzyme in the blood.

Therefore, the procaine ester molecule remains intact for sufficient time to allow it to be transferred into cells throughout the body. Moreover, the procaine acts as a transporting agent and helps to carry the complexing organic acid into the cells also.

A

wdr 0~"s Q 0 4 0 00 I 0 0 I I t 0 0 0 16 Once in the cell, the complex dissociates into the various complexing acids and procaine. The procaine hydrolyses into diethylaminoethanol (DEAE) and paraaminobenzoic acid (PABA). The PABA helps to increase ATP production. The DEAE is split by action of a dealkylating enzyme into ethanolamine. Further enzymatic oxidation of the ethyl groups split from the DEAE results in the formation of two acetyl groups which are transferred into the ion pool or utilized for the preparation of acetylcholine. The ethanolamine functions as a precursor for the preparation of various phospholipids. The ethanolamine is reacted with a phosphatidyl radical to form phosphatidyl ethanolamine, also known as phosphatidyl colamine, which is present in the brain and is the major 15 component of the inner lipid layer of all cell membranes.

Through the action of S-adenosine methionine, a methyl donor in transmethylation reactions, the phosphatidyl ethanolamine is further converted to phosphatidyl choline, also more commonly known as lecithin, which is the major component of the outer lipid layer of all cell membranes.

In addition, ethanolamine can be methylated with S-adenosine methionine to form choline which reacts with acetyl groups to form acetyl choline which is responsible for transmission of nerve impulses.

The stabilization of pcocaine in double salt complex form to enable it to be transported directly to the cells where it is broken down into vitamin acids, DEAE and PABA is of extreme importance in cellular repair. Lecithin and other phospholipids, for example, are generally hydrolyzed 30 in the small intestine by enzymatic action and thus fail to reach the site of damaged cells where they are needed for cell membrane repair. Thus, procaine, if kept intact, functions in a manner similar to a vitamin being a viable source of PABA and DEAE to damaged cells. Damaged cells often have difficulty in transferring nutrients across the 0 0 0 t

-J

4. 1 17 cell membranes. However, the procaine double salt complexes of the present invention are believed to be efficiently transferred intact across damaged membranes bringing to the cells sources of vitamins, DEAE and PABA for immediate cell regeneration and repair.

As the membrane repair progresses, the functions of the cellular sodium and calcium pumps are increased, removing unwanted excesses of these minerals from the cell. Preferably, the compositions of this invention are formulated with sources of potassium and magnesium. The potassium and magnesium replace the sodium and calcium in the cells resulting in higher membrane potentials. This, in turn, improves feeding and the function of enzyme systems in the cell. These changes, along with others not understood, bring about a cellular repair process which inhibits cell degeneration and, in some cases, is believed I o to cause a reversal in many cell degenerative processes.

o o, 0 One particular advantage of the present invention is oo.: its low toxicity. The oral toxicity of the compositions prepared in Example I is extremely low. In rabbits, the is in excess of 800 mg/kg of body weight. Based on procaine HCI content of the complex, a dose easily ooo9 supported by animals is 100 mg/kg of body weight with an acceptable therapeutic dose being 1.66 mg/kg. That is a .o safety factor of at least 60. Moreover, since the active ingredients are vitamins or break into vitamin type compounds, there is almost total absence of side effects.

Hence, as cellular repair agents, the complexes of 0 a procaine salts and vitamin or other type acids are safe, 0 30 relatively free from side effects and provides and 0 oo excellent means to provide the cell with the needed components to instigate the cellular repair processes.

Although single double salt complexes are effective in all cell types of treatment, the composition of Example 1 has been found to be generally more effective in providing i 18 ao ciol o i*4 4444 4*4 4 I t o f4 (1

II

4 4 0 a l 04*0 0000 0 *1 ft 4 4 0 cellular repair in a larger variety of conditions.

Thirty people (10 males and 20 females) ranging in age from 27 to 71 years, having diagnosed rheumatoid arthritis, were treated with the combined complex of Example I. All subjects had been arthritic for a number of years with some of the older subjects being crippled with calcified lumps about the finger joints. Each subject was treated with a starting dosage of 2 100 mg.

tablets (based on procaine HCl) per day taken on an empty stomach. The tablet were administered six to eight hours apart. Three subjects noticed reduced pain and greater joint mobility within the first three days. By the end of of the first month twenty seven subjects experienced almost no pain and greater movement of the joints.

15 Starting the second month the dosage was increased to 4 100 mg. tablets (based on procaine HCl) per day taken on an empty stomach. Two tablets were taken in the morning and two were taken six to eight hours later in the afternoon. By the end of three months twenty eight 20 subjects were pain free and had discontinued taking pain medication. The older subject with calcified joint nodules noted that the nodules reduced in size and further noted improvement in hand movement and gripping ability.

At the end of one year twenty nine subjects continued to experience no pain and had improved joint mobility. One female subject dropped out due to an apparent allergy to procaine HC1.

While the results in the above study are based on subjective determinations reported by the subjects it does 30 demonstrate the positive effect double salt complexes of procaine HCI has on subjects suffering from rheumatoid arthritis. Other benefits were also noticeable. Of the thirty subjects who participated in the above study, three of the females suffered PMS which was controlled while

_A

z r

I

19 taking the procaine HCl double salt complexes. All subjects reported noting improved energy levels, improved sleep habits and less tendency for depression. Two subjects were taking anti-depressant medication and were able discontinue such medication while taking the procaine HCl double salt complexes.

The above description is considered as sufficient to teach one skilled in the art how to make the compositions and practice the invention. However, other embodiments not specifically disclosed will be obvious to one engaged in this art. Therefore, the following claims are meant to include all operable embodiments of the invention within the scope of the claims, whether or not specifically disclosed in the specification, and their functional 15 equivalents.

0oo o o0 0 000C 000 0 0 00 0 o 0 C Q00 C 0 0 ooooo Sor 0 0 000 0 000 0 0o oo ooooo oooo 0 0 00co 0 Q 9 o 0 0 C rro cL a c o 0 0 o 00 :I r

I

i, ii 4.

i

Claims (15)

1. A double salt complex formed from the reaction between stoichiometric amounts of a biologically active organic acid with a procaine salt having the following formula: C 2 H C O-CH 2 CH 2 -N NH 3 A- Cl1 C 2 H whereas A is the anion of a biologically active organic acid selected from the group consisting of vitamin acids, essential unsaturated fatty acids, C 4 to C 6 hydroxy carboxylic acids, and alpha amino acids.

2. A double salt complex according to Claim 1 wherein A is the anion of an acid selected from the group consisting of nicotinic acid, folic acid, biotin, citric acid, ascorbic acid, pantothenic acid, succinic acid, fumaric acid, qluconic acid, linolenic acid, linoleic acid, methionine, tryptophane, tyrosine, glycine, dimethylglycine and glutamic acid and mixtures thereof.

3. A double salt complex according to Claim 2 wherein A is the anion of the acid selected from the group consisting of nicotinic acid, folic acid, biotin, citric acid and ascorbic acid and mixtures thereof.

4. A double salt complex according to Claim 3 wherein the A anion is a mixture of nicotinic acid, folic acid, 4 ir -r -21- biotin, citric acid and ascorbic acid anions and wherein the molar ratio of folic acid to procaine salt is between about 0.002:1 and 0.004:1; the molar ratio of each nicotinic acid, ascorbic acid and citric acid to procaine hydrochloride is between about 0.3:1 to 0.7:1 and the molar ratio of biotin to procaine hydrochloride is between about 0.004:1 and 0.008:1. A double salt complex formulation according to Claim 4 additionally containing potassium and magnesium salts in amounts sufficient to provide 0.25 to 0.30 equivalents of potassium and 0.30 to 0.35 equivalents of magnesium.

6. A double salt complex according to Claim 3 wherein A is the anion of nicotinic acid.

7. A double salt complex according to Claim 3 wherein A is the anion of folic acid.

8. A double salt complex according to Claim 3 wherein A is the anion of ascorbic acid.

9. A double salt complex according to Claim 3 wherein A is the anion of biotin. A double salt complex according to Claim 3 wherein A is the anion of citric acid. Cott 11. A method of promoting cellular repair to damaged cells in a warm blooded animal which comprises orally administering to said animal an effective amount of the procaine double salt complex of Claim 1.

12. A method according to Claim 11 wherein A of the double salt complex is a anion of an acid selected from the group consisting of nicotinic acid, folic acid, biotin, citric acid, ascorbic acid, pantothenic acid, succinic acid, fumaric acid, gluconic acid, linolenic acid, linoleic acid, methionine, tryptop.ane, tyrosine, glycine, dimethylglycine, glutamic acid and mixtures thereof.

13. A method according to Claim 12 wherein A of the u f^ L T 0 22 double salt complex is an anion of an acid selected from the group consisting of nicotinic acid, folic acid, biotin, citric acid and ascorbic acid and mixtures thereof.

14. A method according to Claim 13 wherein the A anion is a mixture of nicotinic acid, folic acid, biotin, citric acid and ascorbic acid anions and wherein the molar ratio of folic acid to procaine salt is between about 0.002:1 ascorbic acid and citric acid to procaine hydrochloride is between about 0.3:1 to 0.7:1 and the molar ratio of biotin to procaine hydrochloride is between about 0.004:1 and 0.008:1. A method according to Claim 14 utilizing a formulation containing the complex according to Claim 14 additionally containing potassium and magnesium salts in amounts sufficient to provide 0.25 to 0.30 equivalents of potassium and 0.30 and 0.35 equivalents of magnesium. ,16. A method according to Claim 13 wherein A in the double salt complex is the anion of nicotinic acid.

17. A method according to Claim 13 wherein A in the double salt complex is the anion of folic acid.

18. A method according to Claim 13 wherein A in the double salt complex is the anion of ascorbic acid.

19. A method according to Claim 13 wherein A in the double salt complex is the anion of biotin.

20. A method according to Claim 13 wherein A in the double salt complex is the anion of citric acid. DATED this 22nd day of March 1990 ROBERT KOCH Patent Attorneys for the Applicant: F.B. RICE CO. L f